`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US),
`LLC,
`Petitioner,
`
`v.
`
`CIPLA LTD,
`Patent Owner.
`
`Case IPR2020-00368
`Patent 8,163,723
`
`PATENT OWNER MANDATORY NOTICE INFORMATION
`UNDER 37 C.F.R. § 42.8
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.8(a)(3), Patent Owner, Cipla Ltd. (“Cipla”),
`
`hereby files its Mandatory Notices:
`
`A.
`
`Real Party-in-Interest (§ 42.8(b)(1))
`
`The following real parties-in-interest are identified: Cipla Ltd, Meda
`
`Pharmaceuticals Inc., Meda AB, Mylan N.V., Mylan Inc., and Mylan
`
`Pharmaceuticals Inc.
`
`B.
`
`Related Matters (§ 42.8(b)(2))
`
`(1) The following matters involve U.S. Patent No. 8,163,723 (“the ’723
`
`Patent), related U.S. Patent No. 8,168,620 (“the ’620 Patent”), and related U.S.
`
`Patent No. 9,259,428 (“the ’428 Patent”):
`
`• Meda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., No.
`
`1:15-cv00785-LPS (D. Del.) (dismissed on July 28, 2017);
`
`• Meda Pharmaceuticals Inc. v. Perrigo UK FINCO Ltd., No. 1:16-cv-
`
`00794-LPS (D. Del.) (dismissed on July 7, 2017); and
`
`• Meda Pharmaceuticals, Inc. v. Apotex Inc., No. 1:14-cv-01453-LPS
`
`(D. Del.) (dismissed on May 17, 2017).
`
`(2) The following matters involved the related ’620 Patent:
`
`• Argentum Pharmaceuticals LLC v. Cipla Ltd., IPR2017-00807
`
`(PTAB) (terminated by joint motion on May 21, 2018).
`
`(3) The following matters involve co-pending petitions for inter partes
`
`
`
`
`
`
`
`review:
`
`• GlaxoSmithKline Consumer Healthcare Holdings (US) v. Cipla Ltd.,
`
`IPR2020-00369 (pending) (the ’620 patent),
`
`• GlaxoSmithKline Consumer Healthcare Holdings (US) v. Cipla Ltd.,
`
`IPR2020-00370 (pending) (the ’428 patent), and
`
`• GlaxoSmithKline Consumer Healthcare Holdings (US) v. Cipla Ltd.,
`
`IPR2020-00371 (pending) (U.S. Patent No. 9,901,585).
`
`C.
`
`Counsel and Service Information (§§ 42.8(b)(3) and (4))
`
`Patent Owner identifies its lead and backup counsel as shown below:
`
`First Backup Counsel
`Emily J. Greb
`(Reg. No. 68,244)
`Perkins Coie LLP
`33 East Main Street, Suite 201
`Madison, WI 53703
`Greb-ptab@perkinscoie.com
`Tel: (608) 663-7494
`Fax: (608) 283-4494
`
`
`
`Lead Counsel
`Brandon M. White
`(Reg. No. 52,354)
`Perkins Coie LLP
`700 13th St., NW, Suite 600
`Washington, DC 20005
`White-ptab@perkinscoie.com
`Tel: (202) 654-6206
`Fax: (202) 654-9681
`Backup Counsel
`Nathan K. Kelley
`(Reg. No. 45,295)
`Perkins Coie LLP
`700 13th St., NW, Suite 600
`Washington, DC 20005
`Kelley_nathan-ptab@perkinscoie.com
`Tel: (202) 654-3343
`Fax: (202) 654-9574
`
`Please address all correspondence to the lead and backup counsel at the above
`
`
`
`
`
`
`
`
`
`addresses and to dymista@perkinscoie.com. Patent Owner consents to electronic
`
`service to the e-mail addresses above for lead and backup counsel and to
`
`dymista@perkinscoie.com.
`
`D.
`
`Patent Owner Preliminary Response
`
`Patent Owner reserves the right to file a preliminary response at a separate
`
`date.
`
`E.
`
`Patent Owner Power of Attorney
`
`A Power of Attorney to transact all business in the United States Patent and
`
`Trademark office in connection with above-referenced Inter Partes Review from
`
`Patent Owner Cipla Ltd. to the above-designated counsel at Perkins Coie LLP is
`
`being filed concurrently with these Mandatory Notices.
`
`Date: February 21, 2020
`
`
`
`
`
`
`
`Respectfully submitted,
`/s/ Brandon M. White
`Brandon M. White
`Reg. No. 52,354
`
`Counsel for Cipla Ltd.
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`Pursuant to 37 C.F.R. § 42.6, I hereby certify that the foregoing Patent
`
`Owner Mandatory Notice Information Under 37 C.F.R. § 42.8 was served on February
`
`21, 2020, by filing this document through the Patent Trial and Appeal Board End to
`
`End System, as well as delivering a copy via electronic mail upon the following
`
`attorneys of record for the Petitioner:
`
`Charles E. Lipsey, charles.lipsey@finnegan.com,
`
`Trenton A. Ward, trenton.ward@finnegan.com,
`
`Richard B. Racine, rich.racine@finnegan.com,
`
`Joann M. Neth, Ph.D., joann.neth@finnegan.com,
`
`Shana K. Cyr, Ph.D., shana.cyr@finnegan.com, and
`
`Cipla-GSK-IPR@finnegan.com.
`
`Date: February 21, 2020
`
`
`
`
`
`Respectfully submitted,
`/s/ Brandon M. White
`Brandon M. White
`Reg. No. 52,354
`
`Counsel for Cipla Ltd.
`
`
`
`
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
